Buspirone Hydrochloride

CHEMBL1200399 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

422.0 g/mol

LogP

—

Phase

4

The hydrochloride salt of buspirone, used for generalized anxiety disorder without the sedative or dependence-causing properties of benzodiazepines. It is taken multiple times daily and requires consistent use over weeks for full benefit. It does not provide immediate relief and is not suitable for as-needed anxiety treatment.

分子量

422.0000 g/mol

TPSA

69.60 Å²

治療領域

Parkinson's Disease Epilepsy Schizophrenia Generalized Anxiety Disorder Gastroesophageal Reflux Disease Stroke Major Depressive Disorder Heart Failure

作用機序

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

Cl.O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1

InChI

InChI=1S/C21H31N5O2.ClH/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20;/h5,8-9H,1-4,6-7,10-17H2;1H

Molecular Formula

C21H32ClN5O2

HBD / HBA

1 / 6

回転可能結合数

6

重原子数

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

The hydrochloride salt of buspirone, used for generalized anxiety disorder without the sedative or dependence-causing properties of benzodiazepines. It is taken multiple times daily and requires consistent use over weeks for full benefit. It does not provide immediate relief and is not suitable for as-needed anxiety treatment.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Buspirone Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200399. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 36431. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Buspirone Hydrochloride PillFYIで

構造

クイックデータ

分子式: C21H32ClN5O2
同義語: 4

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.